DDrare: Database of Drug Development for Rare Diseases

Narsoplimab (DrugBank: Narsoplimab)

3 diseases

ID	Disease name (Link within this page)	Number of trials
66	IgA nephropathy	1
222	Primary nephrotic syndrome	1
223	Primary membranoproliferative glomerulonephritis	1

66. IgA nephropathy [ 199 clinical trials, 214 drugs, (DrugBank: 57 drugs), 32 drug target genes, 128 drug target pathways]

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 199 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong

222. Primary nephrotic syndrome [ 234 clinical trials, 241 drugs, (DrugBank: 78 drugs), 59 drug target genes, 185 drug target pathways]

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong

223. Primary membranoproliferative glomerulonephritis [ 18 clinical trials, 14 drugs, (DrugBank: 7 drugs), 7 drug target genes, 14 drug target pathways]

Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 18 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong